International Clinical Trials Day marked
20 May 2015
Melinda Paton would not be alive today without MIA. Over three years ago, Melinda was told she had only nine months to live due to her stage four melanoma diagnosis. After being transferred to MIA she was placed on an Anti-PD-1 clinical trial.
"I started the Anti-PD-1 trial in September and by December 2013; my tumour had gone from the bowel. When I saw the scan, I was in complete disbelief; I couldn’t believe that it had just disappeared,” says Melinda.
“When I first met with Dr Georgina Long, as a stage 4 patient, the tumour was causing me a lot of pain and I was very weak. The tumours were progressing very quickly and I had surgery in December to have a lymph node removed. After this is when I went onto PD-1, where I noticed a difference almost immediately.
“With PD-1, I don’t have any pain, I’m not tired, and I don’t feel sick. I work full time and it lets me live as normal life as possible. The access to these drugs has been lifesaving, without them there is no doubt I would have died a long time ago.”
Melinda is benefiting from Anti-PD1 immunotherapy treatments and she is able to live as normal life as possible. It is thanks to dedicated clinicians that have discovered these clinical trials that are saving patients lives and improving cancer care globally.
There is still more work to be done. Donate now.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.